Transmitted by the bite of the kissing bug or vinchuca, Chagas disease is a public health problem particularly in poor areas of Latin America and the Caribbean. About eight million people are believed to carry it and about a third of these will develop serious heart or intestinal damage that can lead to death if left untreated.
In September 2009, Eisai and DNDi, an independent, not-for-profit product development partnership based in Geneva, Switzerland, signed a collaboration and license agreement for the clinical development of Ravuconazole for the treatment of Chagas disease. Ravuconazole, an anti-fungal drug discovered and developed by Eisai, has been shown in vitro and in vivo to have activity against the pathogen responsible for Chagas disease.
Under the terms of the agreement, Eisai provides E1224, the prodrug of ravuconazole, as well as its scientific expertise to DNDi for their clinical development to assess the safety and efficacy of this drug. Eisai will also have the option to become the industrial partner with DNDi to manufacture, register and make available E1224 at an affordable price to the public sector in endemic countries.
Phase I studies have already been completed in the USA, demonstrating a well-tolerated safety profile and long half-life. Phase II study results were disclosed in 2013 by DNDi. Eisai is supporting DNDi by supplying E1224 and regularly participates in project team meetings with DNDi.
While DNDi fully utilizes its knowledge, experience and expertise in NTD areas and developing countries, Eisai provides DNDi with its scientific expertise in clinical development as well as supplying the drug for the clinical studies. Eisai has the option to become the industrial partner with DNDi to manufacture, register and make available E1224 at an affordable price to the public sector in endemic countries.
|Location||Latin America and Caribbean, East Asia and Pacific, Bolivia, Switzerland, Japan, United States|